Spark Therapeutics Inc (NASDAQ:ONCE) released its quarterly earnings results on Tuesday. The biotechnology company reported ($1.70) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.36) by $0.34. The firm had revenue of $1.27 million for the quarter, compared to analysts’ expectations of $1.35 million. Spark Therapeutics had a negative net margin of 441.05% and a negative return on equity of 28.28%. The firm’s quarterly revenue was down 1.6% compared to the same quarter last year. During the same period in the previous year, the firm posted ($0.95) EPS.
Shares of Spark Therapeutics (NASDAQ:ONCE) traded down 1.88% during midday trading on Friday, hitting $54.79. 58,304 shares of the stock were exchanged. Spark Therapeutics has a 12-month low of $35.07 and a 12-month high of $65.99. The company’s market cap is $1.71 billion. The firm has a 50-day moving average price of $55.13 and a 200-day moving average price of $56.28.
A number of equities analysts recently commented on the stock. Cantor Fitzgerald reiterated a “buy” rating and set a $94.00 target price on shares of Spark Therapeutics in a research note on Thursday, February 23rd. Jefferies Group LLC set a $59.00 target price on shares of Spark Therapeutics and gave the stock a “hold” rating in a research note on Wednesday, February 22nd. Stifel Nicolaus boosted their target price on shares of Spark Therapeutics from $73.00 to $76.00 and gave the stock a “buy” rating in a research note on Thursday, February 23rd. Wedbush reiterated an “underperform” rating and set a $28.00 target price on shares of Spark Therapeutics in a research note on Wednesday, February 22nd. Finally, JPMorgan Chase & Co. set a $82.00 price target on shares of Spark Therapeutics and gave the company a “buy” rating in a research report on Wednesday, February 22nd. Two analysts have rated the stock with a sell rating, two have assigned a hold rating and nine have assigned a buy rating to the stock. Spark Therapeutics currently has a consensus rating of “Buy” and a consensus price target of $68.31.
In related news, Director Anand Mehra sold 41,910 shares of the business’s stock in a transaction dated Monday, February 27th. The stock was sold at an average price of $65.02, for a total value of $2,724,988.20. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CFO Stephen W. Webster sold 10,000 shares of the business’s stock in a transaction dated Tuesday, April 25th. The shares were sold at an average price of $55.18, for a total value of $551,800.00. Following the completion of the transaction, the chief financial officer now directly owns 4,398 shares of the company’s stock, valued at approximately $242,681.64. The disclosure for this sale can be found here. In the last ninety days, insiders sold 190,796 shares of company stock valued at $12,057,667. 9.60% of the stock is owned by insiders.
A number of hedge funds and other institutional investors have recently added to or reduced their stakes in ONCE. BlackRock Inc. boosted its position in Spark Therapeutics by 11,332.0% in the first quarter. BlackRock Inc. now owns 1,840,214 shares of the biotechnology company’s stock worth $98,158,000 after buying an additional 1,824,117 shares in the last quarter. Baker BROS. Advisors LP acquired a new position in Spark Therapeutics during the third quarter worth about $79,180,000. Wellington Management Group LLP boosted its position in Spark Therapeutics by 119.5% in the first quarter. Wellington Management Group LLP now owns 808,782 shares of the biotechnology company’s stock worth $43,140,000 after buying an additional 440,287 shares in the last quarter. Wells Fargo & Company MN boosted its position in Spark Therapeutics by 131.8% in the first quarter. Wells Fargo & Company MN now owns 522,894 shares of the biotechnology company’s stock worth $27,891,000 after buying an additional 297,277 shares in the last quarter. Finally, Norges Bank acquired a new position in Spark Therapeutics during the fourth quarter worth about $8,232,000. Hedge funds and other institutional investors own 83.97% of the company’s stock.
About Spark Therapeutics
Spark Therapeutics, Inc is a gene therapy company. The Company focuses on treating orphan diseases. It has a pipeline of product candidates targeting multiple rare blinding conditions, hematologic disorders and neurodegenerative diseases. Its pipeline includes a product candidate targeting choroideremia (CHM), which is in a Phase I/II clinical trial and a product candidate for hemophilia A, which is in a Phase I/II clinical trial.
Receive News & Ratings for Spark Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spark Therapeutics Inc and related companies with MarketBeat.com's FREE daily email newsletter.